Stoke Therapeutics, Inc. $STOK Shares Acquired by Redmile Group LLC

Redmile Group LLC increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 3.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 4,164,120 shares of the company’s stock after acquiring an additional 130,050 shares during the period. Stoke Therapeutics makes up about 9.0% of Redmile Group LLC’s investment portfolio, making the stock its 3rd largest position. Redmile Group LLC owned about 0.07% of Stoke Therapeutics worth $135,584,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Kestra Advisory Services LLC purchased a new stake in Stoke Therapeutics during the 4th quarter valued at approximately $26,000. KBC Group NV purchased a new position in shares of Stoke Therapeutics in the 1st quarter valued at approximately $36,000. Harbour Investments Inc. grew its stake in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC increased its holdings in shares of Stoke Therapeutics by 41.0% in the fourth quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock valued at $78,000 after purchasing an additional 718 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Stoke Therapeutics by 31.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after purchasing an additional 658 shares during the period.

Stoke Therapeutics Trading Up 0.3%

Shares of STOK opened at $29.39 on Wednesday. The stock’s 50 day moving average is $30.40 and its two-hundred day moving average is $32.06. Stoke Therapeutics, Inc. has a twelve month low of $12.25 and a twelve month high of $40.22. The firm has a market capitalization of $1.83 billion, a PE ratio of -10.46 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The business had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. On average, sell-side analysts predict that Stoke Therapeutics, Inc. will post -3.22 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 1,795 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $30.58, for a total value of $54,891.10. Following the completion of the transaction, the insider owned 34,826 shares in the company, valued at $1,064,979.08. This trade represents a 4.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the transaction, the general counsel owned 18,086 shares of the company’s stock, valued at $541,675.70. This represents a 7.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 11th. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, The Goldman Sachs Group initiated coverage on shares of Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective on the stock. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $43.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.